A new study from Cedars-Sinai Cancer reveals a potential way to overcome tumor resistance to a common chemotherapy drug ...

The 2023 chemotherapy shortage led to a 60% drop in cisplatin use for head and neck cancer, with costly substitutes ...

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival.

This stands for the chemotherapy drugs bleomycin, etoposide and cisplatin. This combination is very good at preventing germ cell cancers from coming back. Rarely, you might have radiotherapy to try ...

This included ovarian cancer cells, which are known to develop resistance to cisplatin treatment in many cases. "Drug resistance is a significant challenge in cancer therapy," said Plebanski ...

Researchers from the RMIT University in Australia and Indian institutions unveiled a gold-based cancer drug with promising ...

Shortages of platinum-based chemotherapy drugs raise concerns as they may lead to increased cancer mortality due to delayed ...

HRD is now used as a biomarker for administering PARP inhibitors or platinum-based chemotherapy (such as cisplatin or carboplatin) to ovarian cancer patients. PARP inhibitors, which are now used ...

This dual action was tested in zebrafish and is effective against various cancer cell types, including ovarian cancer cells, ...

Ovarian cancer is when abnormal cells in the ovary, fallopian tube or peritoneum begin to grow and divide in an uncontrolled way. They eventually form a growth (tumour). If not caught early, cancer ...